AmideBio to Present at TIDES Conference

AmideBio announced today that Dr. Michael Stowell, Chief Technology Officer for AmideBio, will present at TIDES Conference (Oligonucleotide and Peptide® Technology and Product Development). Novus Biologicals is the exclusive worldwide distributor of AmideBio's unique peptides.

The top of Dr. Stowell's presentation will be: "Functional Differences between Synthetic and Recombinant Amyloid Peptides."  The AmideBio team investigated the functional differences between synthetic and AmideBio’s proprietary BioPureâ„¢ amyloid peptides using a combination of biophysical and cell assays. BioPure material has dramatically different properties than synthetically prepared material. The observed differences can be attributed to a combination of very minor N-1 and racemic peptide contaminants. These studies highlight the potential problems associated with synthetic peptides for both basic research and therapeutic applications.

The TIDES Conference will be held at the Hynes Convention Center in Boston, Massachusetts, May 22-25, 2011. TIDES is the only event that covers CMC manufacturing of peptide and oligo therapeutics in an in-depth manner, with the largest showcase of providers of services and technology critical to the field.  TIDES also includes in-depth programming on oligonucleotides therapeutics discovery, peptide discovery and development, and nucleic acids technologies for molecular diagnostics.

About Novus Biologicals (

Novus Biologicals is a biotechnology company whose mission is to accelerate scientific discovery by developing and marketing unique products in the forefront of science.  Novus Biologicals provides primary antibodies, secondary antibodies, conjugated antibodies, proteins, peptides, isotype and loading controls, RNAi, lysates, stem cell lines and antibody labeling kits to the bioscience community.  All of Novus' products are 100% guaranteed to work in the species and applications listed on the datasheet.  By serving niche and emerging markets, Novus Biologicals has formed and will continue to form ongoing partnerships with leading researchers.

About AmideBio, LLC (   

AmideBio, based in Boulder, Colorado, is a biotechnology company focused on providing recombinant peptide research and clinical products for a diverse array of disease research and disease targets. AmideBio maintains a proprietary platform vector technology that addresses the challenges of historically difficult to manufacture peptides by providing products that are reliable (BioPureâ„¢), economical and incorporate environmentally sustainable practices.


NOVUS Contact:                                             AmideBio Contact: 

Amy Chamberlain-Torres                                  Dr. Misha Plam

Product Marketing Manager                              President & CEO

303-730-1950                                                  303-641-3669                               

Release Date: 
Friday, December 24, 2010 - 07:00